**Figure S1**. Flow diagram of study selection based on PRISMA flow diagram

Studies excluded, with reasons (n = 82)

Reasons for exclusion:

* No ACR/EULAR data at 22-30 weeks n=17.
* Some patients prior biologics n=13.
* Unlicensed application n=16.
* Study design n=10.
* Second-line bDMARD n=21.
* DAS at baseline not reported n=3.
* Population mix of MTX-naïve and cDMARD- experienced n=2.

Trials included in quantitative synthesis   
(n = 46)

Total records   
(n =34,639)

Records excluded at title and abstract sift (n=34,474)

Records screened   
(n = 34,639)

Additional records identified through other sources  
(n =18)

Records identified through database searching after duplicates removed  
(n =34,621)

**Eligibility**

i

f

i

c

a

t

on$

ation

**Screening**

i

f

i

c

a

t

on$

ation

**Identification**

i

f

i

c

a

t

on$

ation

**Included**

i

f

i

c

a

t

on$

ation

Full-text articles assessed for eligibility   
(n = 165 articles of 128 studies)